Clinical Trial Detail

NCT ID NCT02307240
Title Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Curis, Inc.
Indications

Advanced Solid Tumor

Her2-receptor negative breast cancer

Therapies

CUDC-907

Age Groups: adult

Additional content available in CKB BOOST